Key indicators: single-crystal X-ray study; T = 200 K; mean (C-C) = 0.004 Å; disorder in solvent or counterion; R factor = 0.052; wR factor = 0.156; data-toparameter ratio = 14.9.
The title compound, C 16 H 20 N 4 O 3 SÁ0.25CH 4 OÁ0.25H 2 O, is a hydrate/methanol solvate of torasemide, a diuretic drug used in the treatment of hypertension. The asymmetric unit contains two torasemide molecules and half-occupied methanol and water molecules. It is isomorphous with the previously reported nonsolvated T-II form of torasemide. The water molecules contribute to the stability of the structure by participating in an extensive system of O-HÁ Á ÁO hydrogen bonds; N-HÁ Á ÁN and N-HÁ Á ÁO hydrogen bonds are also present. Both asymmetric molecules of torasemide form inversion dimers in the crystal.
Related literature
For background on the medicinal properties and polymorphism of torasemide, see: Uchida et al. (1991) ; Broekhuysen et al. (1986) ; Ghys et al. (1985) ; Ishido & Senzaki (2008) ; Cosin & Diez (2002) ; Murray et al. (2001) ; Dupont et al. (1978) ; Danilovski et al. (2001) .
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). 
D-HÁ
Data collection: CrysAlisPro CCD (Oxford Diffraction, 2006); cell refinement: CrysAlisPro CCD; data reduction: CrysAlisPro RED (Oxford Diffraction, 2006); program(s) used to solve structure: SIR97 (Altomare et al., 1999); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: ORTEP-3 (Farrugia, 1997) and PLATON (Spek, 2009) ; software used to prepare material for publication: SHELXL97 (Sheldrick, 2008) , WinGX (Farrugia, 1999) and PARST (Nardelli, 1995) . 
Comment
Torasemide has been developed as a longlasting loop diuretic that combines the effects of both furosemide and spironolactone (Uchida et al., 1991; Broekhuysen et al., 1986; Ghys et al., 1985) . It is used in the treatment of hypertension and of edema associated with congestive heart failure (Ishido & Senzaki, 2008) . Torasemide has been reported to be more effective than furosemide in chronic heart failure, with a lower mortality (Cosin & Diez, 2002; Murray et al., 2001) .
Three polymorphic forms have been reported up to now for torasemide, denoted T-I, T-II (Dupont et al., 1978) and T-N (Danilovski et al., 2001) . We have obtained crystals of a solvate (I) which, besides being isomorphous with form T-II (with the a and c unit cell axes interchanged), contains water and methanol molecules interspersed in the lattice. The solvate molecules are disorderly arranged in proximity of a twofold rotation axis and one molecule of each type resides, with 0.50 occupancy, in the asymmetric unit of the monoclinic unit cell which comprises, in addition, two independent torasemide molecules ( Fig. 1) , as found for form T-II. Although data collection for I was carried out at a temperature of 200 K, only a 0.8% decrease in the cell volume was found with respect to the room-temperature value of T-II; this might be ascribed in part to the presence of the additional solvate molecules in the lattice of I. The 200 K data collection temperature represented a compromise between conditions of high thermal motion at room temperature, particularly affecting the terminal methyl groups of the chain, and crystal deterioration at lower temperatures. The conformations of the two independent molecules in the structure of I (respectively formed by carbon atoms C1 to C16 and C17 to C32, hereafter referred to as molecules A and B, in the above order, for consistency with previous notation) are similar to those of the A and B molecules of the T-II form, with an 8.4° largest difference in the value of the C22-N8-C23-C24 torsion angle (this corresponds to the C6-N4-C7-C9 chain of molecule B of the T-II form, according to Dupont's notation for the non-solvated form). The present values of the dihedral angles between the best planes through the phenyl and pyridyl rings in the two molecules, of 61.18 (7)° (A) and 78.71 (7)° (B), match those reported (61.2° and 79.1°) for the corresponding molecules of form T-II.
It should be noted that the present set of data, contrary to the older one for T-II, has allowed to assign unambiguously and refine the positions of all hydrogen atoms attached to the N atoms in the two molecules. In particular, the N-H amine bond formed by N1 in molecule A and by N5 in B, is almost parallel, in each case, to the plane of the pyridyl ring, yielding a substantially planar immediate environment of the nitrogen atom, whereas such bond is considerably displaced from the plane of the phenyl ring. This may rationalize the large difference, ca 0.09 Å, between the lengths of the two N-C bonds formed by N1 and, respectively, N5 in the two molecules. Indeed, as a consequence of the above N-H bond orientations, the nitrogen lone pair may favourably interact with antibonding orbitals of the pyridyl ring, but not with those of the phenyl ring, yielding shorter N1-C1 and N5-C17 bonds compared to the N1-C10 and N5-C26 ones (with the additional consequence that the two contiguous C-C bonds in each pyridyl ring are the longest of all bonds in the present rings).
The crystal structure is stabilized by an extensive system of hydrogen bonds (Table 1) 
Experimental
Samples of torasemide were kindly provided by SIMS (SIMS srl, Reggello Firenze, Italy). Crystals of (I), in the form of colourless prisms suitable for X-ray diffraction analysis, were obtained by slow evaporation from 2:1 methanol:butanol solutions. The presence of a small amount of water molecules in the structure may be rationalized considering that the operations were not performed in completely anhydrous conditions.
Refinement
H atoms bound to carbon atoms were in geometrically generated positions, riding. The coordinates of those bound to the N atoms of the torasemide molecules were refined freely, whereas those of H atoms of the solvent molecules were refined with Primary atom site location: structure-invariant direct methods Extinction coefficient: 0.00135 (17)
Special details
Geometry. 
